Technology

GenScript Biotech Collaborates with Singapore Institute of Technology on Talent Development and Applied Research Projects

Published

4 years ago

May 26, 2022

Singapore, May 26, 2022 /PRNewswire/ — GenScript Biotech Corporation (“GenScript”, Stock Code: 1548.HK) and the Singapore Institute of Technology (SIT) signed a Memorandum of Understanding (MoU) today to develop Continuing Education and Training (CET), work-study degree programmes and explore applied research project opportunities. This partnership allows students from SIT to gain global exposure in biotechnology and equip them with industry-relevant skills.

Under the agreement, GenScript will provide internship, full-time employment, industry networking and field service project opportunities for SIT students across several disciplines. As a global biotechnology company, GenScript will leverage its extensive network and deep expertise to provide SIT students with opportunities to gain solid real-world experience. Through the collaboration, SIT students will gain opportunities to work in GenScript China or Singapore, allowing them to gain a greater understanding of the global biotechnology industry, and develop effective interpersonal skills and behaviours to work in a cross-cultural setting. SIT students will also have opportunities to network and establish professional contacts within the sector, and emerge industry-ready when they graduate.

The MoU signing ceremony took place at GenScript Biotech’s Singapore office and was attended by key representatives from both GenScript and SIT.

The MOU signing ceremony was represented by (from left): Dr Yanfeng Li, Head of Singapore Production Operation Department, GenScript; Ms Hui Wang, COE Head of Human Resource Department, GenScript; and Mr Bernard Nee, Vice President (Industry & Community), SIT.

Mr. Bernard Nee, Vice President (Industry & Community), SIT said, “As Singapore’s University of Applied Learning, our applied learning pedagogy embraces experiential and authentic learning. We are appreciative of the partnership with GenScript that will support SIT to produce talents who are equipped with the necessary knowledge and skill sets to deliver positive impact and value within the biotechnology innovation ecosystem. Our students will benefit from the work attachments, employment, industry networking, and field service project opportunities that GenScript provides.”

Ms. Hui Wang, COE Head of Human Resources Department, GenScript, said, “As a global biotechnology company, GenScript puts significant importance to the acquisition and development of talents by encouraging and implementing academy-industry cooperation. With the dual system, we aim to develop talents with highly skilled technology to improve the company’s core competence and meet future needs.”

GenScript Biotech Corporation

GenScript Biotech Corporation (HK.1548) is the world’s leading technology and service provider of life science R&D and manufacture. Built upon its solid gene synthesis technology, GenScript Biotech is divided into four major platforms including the life science service and product platform, the biologics contract development and manufacturing organization (CDMO) platform, the global cell therapy platform and the industrial synthesis biological product platform.

GenScript Biotech was founded in New Jersey, US in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript Biotech’s business operations span over 140 countries and regions worldwide with legal entities located in the US, Mainland China, Hong Kong, Japan, Singapore, the Netherlands and Ireland. GenScript Biotech provides premium, convenient and reliable services and products for over 180,000 customers.

As of December 31, 2021, GenScript Biotech had more than 5,200 employees globally, over 40% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript Biotech owns a number of intellectual property rights, including over 180 patents, over 670 pending patent applications and great numbers of trade secrets.

Driven by the corporate mission of “making people and nature healthier through biotechnology”, GenScript Biotech strives to become the most trustworthy biotech company in the world. As of December 31, 2021, 65,600 peer-reviewed journal articles worldwide have cited GenScript Biotech’s services and products.

For more information, please visit GenScript Biotech’s official website

https://www.genscript.com.

About the Singapore Institute of Technology

The Singapore Institute of Technology (SIT) is Singapore’s first University of Applied Learning, offering specialised degree programmes that prepare its graduates to be work-ready professionals. With a mission to develop individuals and innovate with industry to impact the economy and society in meaningful ways, SIT aims to also be a leader in innovative workplace learning and applied research.

The University’s unique pedagogy integrates work and study, embracing authentic learning in a real-world environment through collaborations with key strategic partners. Its focus on applied research with business impact is aimed at helping industry innovate and grow. The University’s centralised campus in Punggol, when ready in 2024, will feature a fit-for-purpose campus within the larger Punggol Digital District, where academia and industry will be tightly integrated with the community.

For more information, visit www.SingaporeTech.edu.sg.

SOURCE Genscript

Technology

Solventum to Participate in the 2026 Wells Fargo Healthcare Conference

Published

21 minutes ago

September 2, 2026

EAGAN, Minn., Sept. 2, 2026 /PRNewswire/ — Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, Sept. 9, 2026, beginning at approximately 10:15 a.m. EDT in Boston, MA.

A live and archived replay of the fireside chat will be available on the company’s website at investors.solventum.com.

About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers’ toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients’ lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/solventum-to-participate-in-the-2026-wells-fargo-healthcare-conference-302866340.html

SOURCE Solventum

Technology

Etsy to Participate in Upcoming Investor Conference

Published

21 minutes ago

September 2, 2026

BROOKLYN, N.Y., Sept. 2, 2026 /PRNewswire/ — Etsy, Inc. (NYSE: ETSY), which operates the Etsy marketplace that connects millions of passionate and creative buyers and sellers around the world, today announced that its executives will participate in the Goldman Sachs Communacopia and Technology Conference in San Francisco. There will be a webcast fireside chat on September 9, 2026 at 10:50 a.m. PT, which investors can listen to on our investor relations website at investors.etsy.com.

About Etsy

Etsy, Inc. owns and operates the Etsy marketplace, the global destination for unique and creative goods, connecting millions of creative entrepreneurs with buyers around the world. In a time of increasing automation, it’s our mission to keep human connection at the heart of commerce. That’s why we built a place where creativity lives and thrives because it’s powered by people. We help our community of sellers turn their ideas into successful businesses. Our platform connects them with millions of buyers looking for an alternative—something special with a human touch, for those moments in life that deserve imagination.

Etsy was founded in 2005 and is headquartered in Brooklyn, New York.

Etsy has used, and intends to continue using, its Investor Relations website and the Etsy News Blog (etsy.com/news) to disclose material non-public information and to comply with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website and the Etsy News Blog in addition to following our press releases, SEC filings, and public conference calls and webcasts.

Investor Relations Contact:
ir@etsy.com
Media Relations Contact:
press@etsy.com

View original content:https://www.prnewswire.com/news-releases/etsy-to-participate-in-upcoming-investor-conference-302867942.html

SOURCE Etsy, Inc.

Technology

ICF to Present at the 2026 Jefferies Global Industrials Conference

Published

21 minutes ago

September 2, 2026

RESTON, Va., Sept. 2, 2026 /PRNewswire/ — ICF (NASDAQ:ICFI), a leading global solutions and technology provider, today announced its participation at the 2026 Jefferies Global Industrials Conference in New York City. ICF Chief Executive Officer John Wasson and Senior Vice President of Digital Modernization and Experience David Birken will participate in a fireside chat at 8:50 a.m. Eastern Time on Wednesday, September 9.

A live webcast of the fireside chat will be available at https://event.summitcast.com/view/e82pfcbT4UwH79PoqVE5jB/bAAMdsp63mf7QVVFqYCEZ7. The replay will be available for 90 days following the conference.

About ICF
ICF is a leading global solutions and technology provider. At ICF, business analysts and policy specialists work together with digital strategists, data scientists and creatives. We combine unmatched industry expertise with cutting-edge engagement capabilities to help organizations solve their most complex challenges. Since 1969, public and private sector clients have worked with ICF to navigate change and shape the future. Learn more at icf.com.

Caution Concerning Forward-looking Statements
Statements that are not historical facts and involve known and unknown risks and uncertainties are “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995, as amended. Such statements may concern our current expectations about our future results, plans, operations and prospects and involve certain risks, including those related to: the government contracting industry generally; our dependence on contracts with U.S. federal, state and local, and international government clients for the majority of our revenue; failure by Congress or other governmental bodies to approve budgets and appropriations in a timely fashion, reductions in government spending, and the impact of a lengthy federal government shutdown; the current Administration’s policy changes, executive orders, and failure to spend Congressionally mandated appropriations, including the resulting effect on government audits and contract terminations; changes in federal government budgeting and spending priorities; our ability to estimate and control costs under our fixed-price contracts; the realization of our backlog; the dependence of our commercial work on sectors of the global economy that are highly cyclical; and our ability to acquire and successfully integrate businesses. These and other factors that could cause our actual results to differ materially from those indicated in our forward-looking statements are described in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2025, and in our subsequent filings with the Securities and Exchange Commission. The forward-looking statements included herein are made only as of the date hereof, and we specifically disclaim any obligation to update these statements in the future.

Investor information contact:
Lynn Morgen, AdvisIRy Partners, lynn.morgen@advisiry.com, +1.212.750.5800
or
David Gold, AdvisIRy Partners, david.gold@advisiry.com, +1.212.750.5800

Company information contact:
Lauren Dyke, ICF, lauren.dyke@icf.com, +1.571.373.5577

View original content to download multimedia:https://www.prnewswire.com/news-releases/icf-to-present-at-the-2026-jefferies-global-industrials-conference-302867882.html

SOURCE ICF